Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Trial of BM-hMSCs-DNX2401 in Recurrent High-Grade Glioma
NCT03896568Phase 1Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Feb 2019
- Primary completion
- Sep 2027
- Modality
- Gene Editing, Gene Silencing, Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 1, open-label trial of Ad5-D24RGD in glioma (2 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Maximum-tolerated dose at 28 days and Incidence of adverse events at 1 year. Started Feb 2019; status: recruiting.
02
Drugs
Ad5-D24RGD
03
Conditions
glioma
Beyond the preview
Go deeper on NCT03896568.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03896568.